NNextResearch
Sign up

Anthem Biosciences ANTHEM

Bengaluru CRDMO covering small molecules, peptides, oligos and fermentation-based specialty ingredients

Mapped in 1 theme: Pharmaceuticals.

From publicly available information

Where Anthem Biosciences sits in the supply chain

Anthem Biosciences appears in 1 supply-chain layer in one theme, Pharmaceuticals.

Pharmaceuticals › CDMO & contract research

Direct supplier

Other companies in this layer

Divi's LaboratoriesSyngene InternationalSai Life SciencesCohance LifesciencesPiramal PharmaLaurus LabsNeuland LaboratoriesDishman Carbogen AmcisHikalAkums Drugs & Pharmaceuticals
View in the 3D map →

Revenue and profit

₹ CrFY24FY25FY26
Revenue1,4191,8452,124
Net profit367451592

Latest-year revenue ₹2,124 Cr (FY26, company-wide). Wider screens show FY22 onwards.

Strengths

  • Very high margins and ROCE for a CRDMO
  • Profit up 31% in FY26

Risks

  • Listed only in Jul 2025 - short public track record
  • Revenue concentrated in a few late-stage/commercial molecules

Common questions

What does Anthem Biosciences do?

Bengaluru CRDMO covering small molecules, peptides, oligos and fermentation-based specialty ingredients.

Where does Anthem Biosciences sit in the supply chain?

Anthem Biosciences (NSE: ANTHEM) is mapped in 1 supply-chain layer: CDMO & contract research (Pharmaceuticals).

Who are Anthem Biosciences' peers?

In the CDMO & contract research layer of Pharmaceuticals: Divi's Laboratories, Syngene International, Sai Life Sciences, Cohance Lifesciences, Piramal Pharma, Laurus Labs and 4 more.

What is Anthem Biosciences' market cap and valuation?

As of 30 Oct 2026: market cap ₹46,642 Cr, P/E 78.6x, ROCE 30.4%, ROE 22.3%, dividend yield 0.24%.